Akebia Therapeutics
CompanyUnited StatesFounded 2007
Akebia Therapeutics develops one asset, in phase 2 (praliciguat in focal segmental glomerulosclerosis). Mostly small molecule acting on GUCY1A1 and GUCY1B1; based in the United States, founded in 2007.
- 1
- Asset
- Furthest
- Phase 2
- 3
- Trials
- 0
- Signals
Pipeline
1Stimulates soluble guanylate cyclase (sGC) to increase cyclic GMP production.
Phase 2, Small molecule, GUCY1A1, GUCY1B1, focal segmental glomerulosclerosis
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Trials3
- Signals1
- Similar companies5
Updated 8 Oct 2026 · 6 sources